FLT3-ITD-positive AML with a high allele ratio (>0.5) had a poor prognosis; midostaurin combined with the MDM2 inhibitor NVP-HDM201 provides significant therapeutic effects on the wild-type AML of high allelic FLT3-ITD ratio by targeting P53 and NPM1 (110). The gene discussed is TP53; the disease is acute myeloid leukemia.